CA-TETRATE
12.4.2022 14:09:16 CEST | Business Wire | Press release
Tetrate, founded by creators and maintainers of Istio and Envoy, today announced that Istio service mesh and Envoy proxy now support the Arm® Neoverse™ platform. Arm is the leading technology provider of processor IP and its designs have enabled more than 215 billion chips. Neoverse support enables widely used open source software projects to run faster, with less energy usage and lower total cost of ownership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220412005425/en/
Neoverse is available on a wide range of cloud environments and for large-scale data center environments. Neoverse implementations include AWS Graviton2 processor-based Elastic Compute Cloud (Amazon EC2) instances, which offer a price/performance improvement of up to 40% over comparable x86-based instances.
“The diversity of applications is rapidly changing, and Arm is addressing the growing need for increased performance to take on compute-intensive workloads like service mesh,” said Bhumik Patel, director of ecosystem development, Infrastructure Line of Business, Arm. “By partnering with Tetrate to add Istio and Envoy support to Neoverse based platforms, we can bring better application performance, reduced energy consumption and lower TCO to customers of this industry-leading service mesh software.”
Neoverse is particularly well suited for complex workloads such as machine learning, AI, and now, service mesh . For example, AWS previewed Amazon EC2 instances powered by next-generation AWS Graviton3 processors, which will provide up to 25% better performance for compute-intensive workloads compared to current generation instances powered by Graviton2. AWS Graviton3 processors will deliver up to 2x higher floating-point performance for scientific and machine learning workloads, and will provide 50% higher memory bandwidth versus Graviton2-based instances to improve the performance of memory-intensive applications like scientific computing.
“We at Tetrate are seeing larger and more complex service mesh deployments that demand innovative solutions for meeting SLAs cost-effectively from edge to the cloud,” said Saptak Sen, vice president of Strategic Alliances at Tetrate. “We are proud to work with Arm, AWS, and the rest of the Envoy and Istio communities to help our customers in government, finance, ecommerce, and other markets make their mesh implementations more consistent, flexible, and scalable.”
Why Faster Performance is Important for Service Mesh
A service mesh is made up of microservices software instances which are created and destroyed to meet the capacity needs of an application at runtime. Each service instance is accompanied by a proxy instance, and messages between services are routed through the proxy instances.
Each message between services, or between services and the control plane, is authenticated, authorized, and encrypted/decrypted, boosting security. All of this work is compute-intensive, and encryption and decryption in particular are numerically intensive. Faster performance from the underlying hardware infrastructure can make a tremendous difference in the responsiveness of the service mesh.
Istio is the leading service mesh, and Istio software includes an extended version of the Envoy proxy. Tetrate is optimizing Istio and the Envoy proxy for performance. Neoverse supports these efforts and gives a solid boost to Istio and Envoy performance. Accelerating these software projects also yields higher performance when running Tetrate’s industry-leading service mesh management software, Tetrate Service Bridge.
How Istio Service Mesh Delivers for Government and Industry
Istio service mesh, accelerated by Arm Neoverse on multiple platforms, supports a number of benefits important to government and industry:
- Security . Service mesh performs authentication, authorization, and encryption/decryption on every communication among service instances and with the control plane, enhancing security. Neoverse speeds the necessary processing, including numerical processing for encryption and decryption.
- Agility . Service mesh supports rapid software development using continuous integration/continuous delivery (CI/CD) approaches. Neoverse provides a platform for accelerated performance, which can be managed and enhanced across software updates.
- Business continuity . With service mesh, architects can create applications that can fail over from on-premises to cloud, from one availability zone in the cloud to another, and even from one cloud to another. Neoverse support is available on all these platforms, giving applications consistent performance optimization across all deployment targets.
Download Arm-Ready Versions of Istio
Those interested can download Arm-ready versions of Istio from Tetrate Labs. Options include a FIPS version, compliant with Federal Information Processing Standard (FIPS) 140-2, Security Requirements for Cryptographic Modules. And the number of options for accessing Istio running on Neoverse across multiple platforms is large and growing. To learn more, contact Tetrate .
About Arm
Arm technology is at the heart of a computing and data revolution that is transforming the way people live and businesses operate. Our energy-efficient processor designs and software platforms have enabled advanced computing in more than 215 billion chips and our technologies securely power products from the sensor to the smartphone and the supercomputer. Together with 1,000+ technology partners we are at the forefront of designing, securing and managing all areas of AI-enhanced connected compute from the chip to the cloud.
About Tetrate
Started by Istio founders to reimagine application networking, Tetrate is an enterprise service mesh company managing the complexity of modern, hybrid cloud application infrastructure. Its flagship product, Tetrate Service Bridge, provides an edge-to-workload application connectivity platform to deliver business continuity, agility, and security for enterprises on the journey from traditional monoliths to the cloud. Customers get consistent, baked-in observability, runtime security and traffic management in any environment. Tetrate remains a top contributor to the open-source projects Istio and Envoy Proxy. Find out more at www.tetrate.io .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005425/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 11:15:00 CEST | Press release
The first SaaS SuperApp for startups and VCs capitalizes on a $25M round a from Nimbus Capital and a +15% stock surge, unveiling a v3/v4 roadmap that bridges public equity with digital asset liquidity. HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026061293689
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release
Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom